Allure Labs, Inc. – FDA Warning Letter, Nov 22, 2010

On May 24, 2011, the FDA issued a Warning Letter to Allure Labs, Inc. following an inspection from October 18 to November 22, 2010. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations (21 CFR Parts 210 and 211), rendering their drug products adulterated.

Key violations include: 1. **Inadequate Quality Control Unit (QCU):** The QCU failed to reject out-of-specification components, detect microbial miscalculations leading to the release of OOS products, and identify discrepancies in sample weights and dilution factors, resulting in the release of non-conforming products. The firm's response regarding employee termination was insufficient, lacking details on affected lots, reporting to distributors, or a timeframe for corrective actions. 2. **Lack of Procedures for Objectionable Microorganisms:** The firm's microbial limit specifications for finished products were inadequate, potentially allowing objectionable organisms. They also failed to test for *Staphylococcus aureus* or *Pseudomonas aeruginosa* in topical products. The proposed review of raw material specifications was insufficient as it did not include finished products or a timeframe. 3. **Unsound Specifications and Test Procedures:** The firm lacked scientific justification for bulk drug sampling, used contaminated spatulas, failed to validate microbiological testing SOPs, and did not verify assay methods for active ingredients. Proposed actions lacked specific timeframes.